News
Important Only
Prediction: This Artificial Intelligence (AI) Stock Will Outperform Nvidia Through 2030
Key PointsNvidia relies on Taiwan Semiconductor Manufacturing Company to build its high-demand GPUs.TSMC's business relies less on AI developments than Nvidia's, reducing long-term risks.TSMC's valuation leaves it with more upside than Nvidia's stock, which has a lot of future growth priced into it....The Motley Fool
Wed, Aug 13
US STOCKS-S&P 500, Nasdaq futures at record highs on September rate cut hopes
Futures up: Dow 0.30%, S&P 500 0.20%, Nasdaq 0.24%Traders price in 98% chance of 25 bps Fed rate cut in SeptemberCBOE volatility index hits lowest level since JanuaryCoreWeave falls after larger-than-expected Q2 net lossBy Johann M Cherian and Sanchayaita Roy Aug 13 (Reuters) - Futures track...Reuters
Wed, Aug 13
Is This Underrated Artificial Intelligence (AI) Stock the Next Big Winner?
Key PointsNebius Group is rapidly scaling infrastructure for the AI-focused cloud services market.Nebius spent heavily to expand capacity, yet still grew its cash horde to $1.68 billion as of the end of the second quarter.AI is penetrating sectors well beyond technology, and Nebius will be one big b...The Motley Fool
Wed, Aug 13
Tourmaline Bio Inc reports results for the quarter ended June 30 - Earnings Summary
Tourmaline Bio Inc TRML.OQ reported a quarterly adjusted loss of 90 cents per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -68 cents. The mean expectation of ten analysts for the quarter was for a loss of 94 cents per share. Wall Str...Reuters
Wed, Aug 13
Compass Minerals falls after J.P.Morgan double downgrades to 'underweight'
** Shares of Compass Minerals International CMP.N down 2.1% at $18.8 premarket** J.P.Morgan double downgrades commodity chemicals firm to "underweight" from "overweight"** JPM favors larger agricultural companies like Nutrien and Mosaic on stronger finances, potential tariff benefits...Reuters
Wed, Aug 13
Aura Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Aura Biosciences Inc AURA.OQ reported a quarterly adjusted loss of 47 cents per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -41 cents. The mean expectation of four analysts for the quarter was for a loss of 46 cents per share. Wall ...Reuters
Wed, Aug 13
Sbc Medical Group Posts Weak Fiscal Q2
Key PointsGAAP earnings per share of $0.02 and revenue of $43,358,847 for Q2 FY2025 fell below analyst expectations and marked sharp year-over-year declines.EBITDA margin (non-GAAP) decreased to 35%, down from 53% in Q2 FY2024, reflecting notable margin compression.No forward financial guidance was ...The Motley Fool
Wed, Aug 13
Data center firm TSS slides after launching stock offering
** Data center services firm TSS' TSSI.O shares slide 9.1% to $16.91 premarket** TSSI late Tuesday commenced public offering of shares; size not disclosed** Lucid Capital Markets is the sole bookrunning manager for the offering** Stock closed down 1.2% at $18.60 on Tuesday** Proceeds will be use...Reuters
Wed, Aug 13
The Smartest Energy Stocks to Buy With $1,000 Right Now
Key PointsOne reliable utility has seen the future, and become one of the largest players in the industry's growth machine.One diversified global energy giant is using the profits from its old businesses to build out a new one that's increasingly important to the world.One high-yield stock has a goa...The Motley Fool
Wed, Aug 13
Mersana Misses Fiscal Q2 Revenue Target
Key PointsEarnings per share (GAAP) for Q2 2025 missed analyst expectations, with a net loss of $4.87 compared to an estimated loss of $3.87.Revenue (GAAP) for Q2 2025 was $3.1 million, missing the $6.2 million estimate but up from $2.3 million in the same period of 2024.Cost-cutting efforts led to ...The Motley Fool
Wed, Aug 13
Tourmaline Bio Reports Loss as R&D Rises
Key PointsTourmaline Bio (NASDAQ:TRML) reported a net loss per share (GAAP) of $0.90.The TRANQUILITY trial delivered positive Phase 2 data for pacibekitug in cardiovascular inflammation, with topline results announced during the quarter, supporting best-in-class potential.Cash and investments totale...The Motley Fool
Wed, Aug 13
Sanara MedTech Sales Jump 28 Percent
Key PointsGAAP revenue reached $25.83 million for Q2 2025, beating analyst estimates for the quarter and growing 28% year-over-year.Adjusted EBITDA increased to $2.66 million, more than quadrupling from Q2 2024.Losses at the Tissue Health Plus segment widened during the first half of 2025, prompting...The Motley Fool
Wed, Aug 13
PDSB Loss Improves as Costs Drop
Key PointsNet loss per share (GAAP) improved to ($0.21) in Q2 2025, beating analyst expectations by $0.02 (GAAP).Total operating expenses (GAAP) dropped 12.6% year over year to $7.6 million.No revenue reported as development-stage programs advanced in key clinical trials.These 10 stocks could mint t...The Motley Fool
Wed, Aug 13
Will Starlink SPAC or IPO in 2025?
Key PointsThere are few private companies worth more than SpaceX, and many investors would like to own a piece of it.CEO Elon Musk has shown little interest in taking the rocket part of SpaceX public.However, Musk has been receptive to the idea of a spinoff and subsequent IPO of the Starlink satelli...The Motley Fool
Wed, Aug 13
This Legacy Stock Is Back, Poised for a Major Rebound
Key PointsThe company is embracing its "Tar-zhay" positioning to focus on superior shopping experiences over rock-bottom prices.Target maintains industry-leading profit margins despite recent revenue challenges.The stock's 4.4% dividend yield is near historic highs and far above other retailer stock...The Motley Fool
Wed, Aug 13
Aura Biosciences Posts Q2 Cash Surge
Key PointsMomentum in late-stage clinical development: pivotal Phase 3 CoMpass trial for bel-sar actively enrolling and over 240 patients had been pre-screened for the CoMpass trial as of Q2 2025, with completion targeted by end of 2025.Research and development expenses rose to $22.9 million for the...The Motley Fool
Wed, Aug 13
Performance Food Sales Jump 12 Percent
Key PointsRevenue climbed 11.5% to $16.94 billion in Q4 FY2025, beating analyst expectations by $172 million.Adjusted diluted EPS (Non-GAAP) of $1.55 exceeded the $1.46 consensus.GAAP net income dropped 21.0% to $131.5 million primarily due to increased depreciation, amortization, and interest expen...The Motley Fool
Wed, Aug 13
Compass Therapeutics dips after $120 mln equity offering
** Shares of biopharma firm Compass Therapeutics CMPX.O down 1.3% premarket to $3.13 after $120 mln follow-on priced ** Boston, Massachusetts-based oncology-focused CMPX late Tues announced 40 mln shares, including pre-funded warrants to buy ~6.7 mln shares ** Offering price of $3 is 5...Reuters
Wed, Aug 13
Crown Crafts Sales Drop 4.5 Percent
Key PointsNet sales (GAAP) declined 4.5% to $15.5 million for Q1 FY2026, as the $2.1 million contribution from the Baby Boom acquisition was offset by declines in legacy product categories.Gross profit margin (GAAP) fell to 22.7% as tariffs on imports from China drove up costs.Net loss (GAAP) widene...The Motley Fool
Wed, Aug 13
Street View: FDA nod for Insmed's lung disease drug is 'breath of fresh air'
** The U.S. Food and Drug Administration on Tuesday approved Insmed's INSM.O oral drug, Brinsupri, as the first treatment for non-cystic fibrosis bronchiectasis, a chronic lung disease marked by damaged airways, persistent cough and excess mucus production** At least 6 brokerages raised PT on th...Reuters
Wed, Aug 13
